Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
94.79
+0.63 (0.67%)
At close: Jun 27, 2025, 4:00 PM
94.75
-0.04 (-0.04%)
After-hours: Jun 27, 2025, 7:00 PM EDT
Illumina Employees
Illumina had 10,370 employees as of December 31, 2024. The number of employees decreased by 2,020 or -16.30% compared to the previous year.
Employees
10,370
Change (1Y)
-2,020
Growth (1Y)
-16.30%
Revenue / Employee
$418,226
Profits / Employee
-$93,153
Market Cap
15.01B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10,370 | -2,020 | -16.30% |
Dec 31, 2023 | 12,390 | -970 | -7.26% |
Dec 31, 2022 | 13,360 | 1,610 | 13.70% |
Dec 31, 2021 | 11,750 | 2,400 | 25.67% |
Dec 31, 2020 | 9,350 | 1,650 | 21.43% |
Dec 29, 2019 | 7,700 | 400 | 5.48% |
Dec 30, 2018 | 7,300 | 1,100 | 17.74% |
Dec 31, 2017 | 6,200 | 700 | 12.73% |
Dec 31, 2016 | 5,500 | 900 | 19.57% |
Dec 31, 2015 | 4,600 | 900 | 24.32% |
Dec 28, 2014 | 3,700 | 700 | 23.33% |
Dec 29, 2013 | 3,000 | 800 | 36.36% |
Dec 31, 2012 | 2,200 | -200 | -8.33% |
Dec 30, 2012 | 2,400 | 300 | 14.29% |
Dec 31, 2011 | 2,100 | 319 | 17.91% |
Dec 31, 2010 | 1,781 | 245 | 15.95% |
Dec 28, 2008 | 1,536 | 495 | 47.55% |
Dec 30, 2007 | 1,041 | 445 | 74.66% |
Dec 31, 2006 | 596 | 221 | 58.93% |
Dec 31, 2006 | 375 | 97 | 34.89% |
Dec 31, 2005 | 278 | 42 | 17.80% |
Dec 28, 2003 | 236 | 3 | 1.29% |
Dec 29, 2002 | 233 | 54 | 30.17% |
Dec 30, 2001 | 179 | 74 | 70.48% |
Dec 31, 2000 | 105 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ILMN News
- 5 days ago - Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy - PRNewsWire
- 10 days ago - Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling - Business Wire
- 17 days ago - lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - PRNewsWire
- 4 weeks ago - Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PRNewsWire
- 4 weeks ago - Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies - PRNewsWire
- 5 weeks ago - Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel - Business Wire
- 6 weeks ago - Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90% - Benzinga